newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

  • IGC Pharma is strengthening its regulatory, biostatistical, AI-enabled data science, & strategic development capabilities ahead of expected Phase 2 topline results for IGC-AD1 in Q4 2026.
  • The CALMA trial has randomized 160 participants to date, with up to eight additional randomizations planned before enrollment closure.
  • This final over-enrollment phase aims to enhance the dataset for end-of-treatment, secondary, & exploratory analyses prior to database lock & unblinding.
  • OPIS Research, a global CRO founded in Italy, has been engaged to support regulatory interactions with the European Medicines Agency (EMA).
  • IGC-AD1 is an investigational therapy for agitation associated with Alzheimer's dementia being evaluated in the randomized, double-blind, placebo-controlled CALMA Phase 2 trial.
  • The company's pipeline includes TGR-63 for amyloid plaques & early-stage programs targeting neurodegeneration, tau proteins, & metabolic dysfunction.
  • Forward-looking statements regarding enrollment closure, data readout, regulatory engagement, & potential partnerships are subject to risks that could cause actual results to differ materially from expectations.